Mengyao Li
Seminars
Thursday 23rd July 2026
De-Risking Clinical Translation of Peptide Radiopharmaceuticals: Leveraging Insights from Approved and Emerging Programs to Predict and Mitigate Off-Target Toxicity
11:00 am
- Leveraging literature across approved and emerging radiopharmaceuticals to identify key drivers of clinical success and inform toxicity mitigation strategies
- Evaluating multi-target peptide radionuclide conjugates to optimise tumour uptake while minimising off-target toxicity to organs at risk
- Integrating clinical pharmacology and DMPK data to predict biodistribution, retention and clearance profiles to identify toxicity risks prior to first-in-human studies
- Establishing robust bioanalytical strategies to accurately quantify tissue distribution and radiation dose to define therapeutic window and inform safety thresholds
